Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00255606
First received: November 18, 2005
Last updated: June 25, 2013
Last verified: September 2010